Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Name
INCMOR 0208-301
Description
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Trial arms
Trial start
2021-04-15
Estimated PCD
2024-02-23
Trial end
2028-08-09
Status
Active (not recruiting)
Phase
Early phase I
Treatment
tafasitamab
tafasitamab will be administered IV for 12 cycles
Arms:
Arm A : tafasitamab + rituximab + lenalidomide
Other names:
INCMOR00208, MOR00208
rituximab
Rituximab will be administered IV on cycles 1 - 5
Arms:
Arm A : tafasitamab + rituximab + lenalidomide, Arm B : placebo+rituximab+lenalidomide
lenalidomide
Lenalidomide will be administered PO for 12 cycles
Arms:
Arm A : tafasitamab + rituximab + lenalidomide, Arm B : placebo+rituximab+lenalidomide
placebo
placebo will be administered IV for 12 cycles
Arms:
Arm B : placebo+rituximab+lenalidomide
Size
654
Primary endpoint
Progression Free Survival (PFS) in FL population
Up to 6 years
Eligibility criteria
Inclusion Criteria:
* Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
* Willingness to avoid pregnancy or fathering children
* In the opinion of the investigator, be able and willing to receive adequate mandatory prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or low-molecular-weight heparin)
* Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy
* Documented relapsed, refractory, or PD after treatment with systemic therapy
* ECOG performance status of 0 to 2
Exclusion Criteria:
* Women who are pregnant or breastfeeding.
* Any histology other than FL and MZL or clinical evidence of transformed lymphoma
* Prior non-hematologic malignancy
* Congestive heart failure
* HCV positivity, chronic HBV infection or history of HIV infection
* Active systemic infection
* CNS lymphoma involvement
* Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of Cycle 1
* Prior use of lenalidomide in combination with rituximab
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Double Blind', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 654, 'type': 'ACTUAL'}}
Updated at
2024-03-04
1 organization
4 products
2 indications
Product
tafasitamabIndication
Follicular LymphomaIndication
Marginal Zone LymphomaProduct
rituximabOrganization
IncyteProduct
placeboProduct
lenalidomide